#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	3150	16S	1529	1529	99.93	16S.l6.c4.ctg.1	1963	301.6	0	.	n	.	0	C1450T	SNP	1450	1450	C	1675	1675	T	379	T	224	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	3150	16S	1529	1529	99.93	16S.l6.c4.ctg.1	1963	301.6	1	SNP	n	C1184T	0	.	.	1184	1184	C	1409	1409	C	389	C,A	239,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5740	23S	2890	2890	99.9	23S.l6.c4.ctg.1	3310	315.2	0	.	n	.	0	G1337A	SNP	1337	1337	G	1577	1577	A	269	A	184	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5740	23S	2890	2890	99.9	23S.l6.c4.ctg.1	3310	315.2	0	.	n	.	0	T1971C	SNP	1971	1971	T	2211	2211	C	307	C	191	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5740	23S	2890	2890	99.9	23S.l6.c4.ctg.1	3310	315.2	1	SNP	n	A2045G	1	A2045G	SNP	2045	2045	A	2285	2285	G	325	G	199	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5740	23S	2890	2890	99.9	23S.l6.c4.ctg.1	3310	315.2	1	SNP	n	C2597T	0	.	.	2597	2597	C	2837	2837	C	385	C	244	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_V_01427c	folP.WHO_V_01427c	1	1	27	216	folP	855	855	100.0	folP.l15.c4.ctg.1	1716	25.3	1	SNP	p	R229S	1	.	.	685	687	AGC	1166	1168	AGC	34;34;32	A;G;C	20;20;19	folP.WHO_V_01427c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	582	gyrA	2751	2751	99.93	gyrA.l15.c4.ctg.1	3478	31.2	1	SNP	p	S91F	1	.	.	271	273	TTC	727	729	TTC	46;46;46	T;T;C	27;25;26	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	582	gyrA	2751	2751	99.93	gyrA.l15.c4.ctg.1	3478	31.2	1	SNP	p	D95G	1	.	.	283	285	GGC	739	741	GGC	53;53;53	G;G;C	28;26;26	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	582	gyrA	2751	2751	99.93	gyrA.l15.c4.ctg.1	3478	31.2	1	SNP	p	G95N	0	.	.	283	285	GGC	739	741	GGC	53;53;53	G;G;C	28;26;26	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	27	156	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1587	20.0	1	SNP	p	G45D	0	.	.	133	135	GGC	538	540	GGC	43;43;43	G;G;C	27;26;26	mtrR.WHO_V_01454:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	120	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	694	31.0	0	.	n	.	0	A197.	DEL	197	197	A	364	364	A	50	A	33	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	442	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2806	29.7	0	.	p	.	0	I384V	NONSYN	1150	1152	ATC	1316	1318	GTC	38;40;40	G;T;C	25;24;25	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	442	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2806	29.7	1	SNP	p	D86N	0	.	.	256	258	GAC	422	424	GAC	37;37;37	G;A;C	23;21;22	parC.WHO_V_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	442	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2806	29.7	1	SNP	p	R87W	0	.	.	259	261	CGT	425	427	CGT	35;35;33	C;G;T	22;22;20	parC.WHO_V_00204c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	442	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2806	29.7	1	SNP	p	S87R	1	.	.	259	261	CGT	425	427	CGT	35;35;33	C;G;T	22;22;20	parC.WHO_V_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	442	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2806	29.7	1	SNP	p	R87I	0	.	.	259	261	CGT	425	427	CGT	35;35;33	C;G;T	22;22;20	parC.WHO_V_00204c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	442	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2806	29.7	1	SNP	p	S88P	0	.	.	262	264	TCC	428	430	TCC	32;32;32	T;C;C	19;20;20	parC.WHO_V_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	490	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2833	31.4	0	.	p	.	0	R340C	NONSYN	1018	1020	CGC	1544	1546	TGC	44;44;43	T;G;C	28;28;27	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	490	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2833	31.4	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1754	1756	GGC	32;32;33	G;G;C	21;22;21	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.12.001	penA.12.001	1	1	27	522	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2317	40.1	1	SNP	p	A311V	0	.	.	931	933	GCA	1315	1317	GCA	58;59;59	G;C;A	36;36;37	penA.12.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	522	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2317	40.1	1	SNP	p	I312M	0	.	.	934	936	ATC	1318	1320	ATC	57;57;57	A;T;C	36;35;35	penA.12.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	522	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2317	40.1	1	SNP	p	V316P	0	.	.	946	948	GTG	1330	1332	GTG	54;54;54	G;T;G	34;35;35	penA.12.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	522	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2317	40.1	1	SNP	p	V316T	0	.	.	946	948	GTG	1330	1332	GTG	54;54;54	G;T;G	34;35;35	penA.12.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	522	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2317	40.1	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1834	1836	ACC	24;24;23	A;C;C	14;16;16	penA.12.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	522	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2317	40.1	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1888	1890	GCG	17;17;17	G;C;G	13;13;11	penA.12.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	522	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2317	40.1	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1888	1890	GCG	17;17;17	G;C;G	13;13;11	penA.12.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	522	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2317	40.1	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2011	2013	GGC	13;13;13	G;G;C	8;9;7	penA.12.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	522	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2317	40.1	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2020	2022	GGC	10;10;10	G;G;C	6;8;4	penA.12.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	522	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2317	40.1	1	SNP	p	P552S	1	.	.	1654	1656	TCG	2038	2040	TCG	14;15;15	T,G;C;G	7,1;8;9	penA.12.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	824	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3055	46.8	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1533	1535	CCG	31;31;31	C;C;GC,GCC	17;23;14,1	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	254	porA	1146	1146	99.56	porA.l6.c4.ctg.1	1524	30.7	0	.	p	.	0	M83fs	FSHIFT	247	247	A	403	403	C	19	C	11	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	326	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1669	36.0	0	.	p	.	0	N38E	NONSYN	112	114	AAT	413	415	GAA	44;43;44	G;A;A	28;27;29	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	326	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1669	36.0	0	.	p	.	0	N134D	NONSYN	400	402	AAT	701	703	GAT	43;43;43	G;A;T	29;28;28	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	326	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1669	36.0	0	.	p	.	0	P175S	NONSYN	523	525	CCA	824	826	TCA	32;33;33	T;C;A	20;21;20	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	326	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1669	36.0	0	.	p	.	0	Y211F	NONSYN	631	633	TAC	932	934	TTC	37;37;37	T;T;C	23;19;22	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	326	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1669	36.0	0	.	p	.	0	A218V	NONSYN	652	654	GCC	953	955	GTC	42;44;44	G;T;C	27;26;27	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	326	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1669	36.0	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1283	1285	GCA	47;47;47	G;C;A	32;31;32	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	326	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1669	36.0	1	SNP	p	G120K	1	.	.	358	360	AAG	659	661	AAG	48;48;49	A;A;G	32;30;30	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	326	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1669	36.0	1	SNP	p	A121D	1	.	.	361	363	GAC	662	664	GAC	49;49;49	G;A;C	32;32;33	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	326	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1669	36.0	1	SNP	p	D121N	0	.	.	361	363	GAC	662	664	GAC	49;49;49	G;A;C	32;32;33	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	1516	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	4684	60.6	1	SNP	p	H553N	1	.	.	1657	1659	AAT	1866	1868	AAT	54;55;55	A;A;T	36;36;34	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	192	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	887	44.9	1	SNP	p	V57M	1	.	.	169	171	ATG	394	396	ATG	74;74;76	A;T;G	48;48;50	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
